---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-047487"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T20:28:41.679921+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics board member Bryant Fong resigns; committee chairs reassigned

## Summary
- Bryant Fong resigned from board effective Nov 19, 2024 to focus on other roles; no disagreements.
- Young T. Kwon appointed Chairman of Audit Committee and designated audit committee financial expert.
- Steven A. Elms added to Audit Committee.
- Alison C. Finger added to Governance and Nominations Committee and Compensation Committee.

## SEC filing metadata
- accession: 0001140361-24-047487
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036124047487/0001140361-24-047487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036124047487/ef20038782_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-047487
- JSON: https://secwatch.observer/filing/0001140361-24-047487.json
- Plain text: https://secwatch.observer/filing/0001140361-24-047487.txt

## Key facts
- Executive change
  Bryant E. Fong resigned as member of the Board of Directors at ADMA BIOLOGICS, INC..
  - Action: resigned
  - Role: member of the Board of Directors
  source text: On November 19, 2024, Bryant E. Fong notified ADMA Biologics, Inc. (the “Company”) that he resigned, effective immediately, as a member of the Company’s Board of Directors (the “Board”) and any committees of the Board in order to devote more time to his roles as Managing Director of Biomark Capital Fund and as Partner and Co-Portfolio Manager of Stonepine Capital Management.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036124047487/0001140361-24-047487-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.